Literature DB >> 16144972

Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta.

E Dabbs Loomis1, Jennifer C Sullivan, David A Osmond, David M Pollock, Jennifer S Pollock.   

Abstract

Experiments were designed to test the hypothesis that elevated levels of endothelin 1 (ET-1) in the vasculature activate NADPH oxidase and/or uncoupled nitric-oxide synthase (NOS), resulting in O2-* production, and mediate increased constriction. Rat aortic rings were incubated with ET-1 or vehicle in the presence and absence of superoxide dismutase (SOD), ebselen (glutathione peroxidase mimetic), apocynin (NADPH oxidase inhibitor), L-NAME (Nomega-nitro-L-arginine methyl ester) (NOS inhibitor), tetrahydrobiopterin (BH4) (NOS cofactor), or selective ETA and ETB receptor antagonists (BQ-123 [cyclo(D-Asp-Pro-D-Val-Leu-D-Trp)] and A-192621 [[2R-(4-propoxyphenyl)-4S-(1,3-benzodioxol-5-yl)-1-(N-(2,6-diethylphenyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid]], respectively). O2-* production was monitored by oxidized dihydroethidine staining and/or lucigenin chemiluminescence. ET-1 significantly increased O2-* production compared with vehicle. SOD, ebselen, and apocynin inhibited the ET-1-induced increase in O2-* in intact and endothelium-denuded aorta. L-NAME and BH4 inhibited the ET-1-induced increase in O2-* in intact tissue, whereas these two compounds had no effect on ET-1-induced O2-* in endothelium-denuded aorta. Preincubation with BQ-123 or A-192621, individually, had no effect on ET-1-induced O2-*; however combining both antagonists inhibited the ET-1-stimulated increase in O2-*. Rat aortic rings were incubated with ET-1 or vehicle in the presence or absence of sepiapterin (BH4 synthesis substrate) or apocynin and mounted on wire myographs to determine isometric force generation in response to increasing KCl concentrations. ET-1 increased the contractile response to KCl compared with vehicle. Treatment with either sepiapterin or apocynin attenuated the ET-1-mediated increase with no effect of sepiapterin or apocynin alone. These data support the hypothesis that ET-1 increases vascular tone, in part, through ETA/ETB receptor activation of O2-* production from NADPH oxidase and NOS uncoupling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144972     DOI: 10.1124/jpet.105.091728

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  51 in total

1.  Cross-talk between p(38)MAPK and G iα in regulating cPLA 2 activity by ET-1 in pulmonary smooth muscle cells.

Authors:  Sajal Chakraborti; Animesh Chowdhury; Tapati Chakraborti
Journal:  Mol Cell Biochem       Date:  2014-11-16       Impact factor: 3.396

2.  Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

Authors:  Ahmed A Elmarakby; Jessica Faulkner; Mohammed Al-Shabrawey; Mong-Heng Wang; Krishna Rao Maddipati; John D Imig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-10       Impact factor: 3.619

3.  Endothelin-1-induced endothelial microvesicles impair endothelial cell function.

Authors:  L Madden Brewster; Vinicius P Garcia; Ma'ayan V Levy; Kelly A Stockelman; Anabel Goulding; Noah M DeSouza; Jared J Greiner; Jamie G Hijmans; Christopher A DeSouza
Journal:  J Appl Physiol (1985)       Date:  2020-04-23

4.  Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension.

Authors:  Ahmed A Elmarakby; Jan M Williams; John D Imig; Jennifer S Pollock; David M Pollock
Journal:  Vascul Pharmacol       Date:  2006-09-26       Impact factor: 5.773

5.  Dietary sodium modulates the interaction between efferent renal sympathetic nerve activity and afferent renal nerve activity: role of endothelin.

Authors:  Ulla C Kopp; Olaf Grisk; Michael Z Cicha; Lori A Smith; Antje Steinbach; Torsten Schlüter; Nicole Mähler; Tomas Hökfelt
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-05-27       Impact factor: 3.619

6.  Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation.

Authors:  Giuseppe Faraco; Ana Moraga; Jamie Moore; Joseph Anrather; Virginia M Pickel; Costantino Iadecola
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

7.  Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2 O2 in resistance arteries from patients with cardiovascular disease.

Authors:  Thomas M Leurgans; Maria Bloksgaard; Jonathan R Brewer; Luis A Bagatolli; Maise H Fredgart; Kristoffer Rosenstand; Maria L Hansen; Lars M Rasmussen; Akhmadjon Irmukhamedov; Jo Gr De Mey
Journal:  Br J Pharmacol       Date:  2016-04-06       Impact factor: 8.739

Review 8.  Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.

Authors:  Donald E Kohan; David M Pollock
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

9.  A comparison of reactive oxygen species metabolism in the rat aorta and vena cava: focus on xanthine oxidase.

Authors:  Theodora Szasz; Janice M Thompson; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

10.  Endothelin-1 contributes to endothelial dysfunction and enhanced vasoconstriction through augmented superoxide production in penile arteries from insulin-resistant obese rats: role of ET(A) and ET(B) receptors.

Authors:  A Sánchez; P Martínez; M Muñoz; S Benedito; A García-Sacristán; M Hernández; D Prieto
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.